Acadia Schizophrenia Drug Meets Study Goal in Phase II Trial
SAN DIEGO-- Acadia Pharmaceuticals Inc. said Monday its schizophrenia drug met its goal in a Phase II trial, and shares nearly doubled in value.
The company's ACP-103 trial drug to treat schizophrenia showed a statistically significant level of effectiveness in the trial, which tested the drug used in conjunction with both a generic typical antispsychotic drug, haloperidol, and risperidone, an atypical antipsychotic drug.
Schizophrenia is a chronic, debilitating mental illness characterized by disturbances in thinking, emotional reaction and behavior.
"The use of ACP-103 in co-therapy with risperidone or other modern atypical antipsychotics may result in enhanced efficacy and an improved side effect profile," the company said in a statement.
Nearly all antipsychotics are 5-HT2A receptor inverse agonists, in that they can attenuate the basal constitutive signaling activity of this receptor, in contrast to neutral antagonists that can only block agonist-induced responses. 5HT receptors bind serotonin in the brain.
Acadia shares soared $5.86, or 87.6 percent, to $12.60 in morning trading on the Nasdaq Stock Market.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment